A prognostic risk model for glioma patients by systematic evaluation of genomic variations.
iScience, 2022/12/22;25(12):105681.
Zhang B[1, 2, 3], Wan W[4], Li Z[4], Gao Z[4], Ji N[4], Xie J[4], Wang J[5], Wang B[6], Lai-Wan Kwong D[1, 2], Guan X[1, 2], Gao S[7], Zhao Y[4], Lu Y[8], Zhang L[4], Rodland KD[9], Tsang SX[3]
Affiliations
PMID: 36536675DOI: 10.1016/j.isci.2022.105681
Impact factor: 6.107
Abstract
The overall survival rate of gliomas has not significantly improved despite new effective treatments, mainly due to tumor heterogeneity and drug delivery. Here, we perform an integrated clinic-genomic analysis of 1, 477 glioma patients from a Chinese cohort and a TCGA cohort and propose a potential prognostic model for gliomas. We identify that SBS11 and SBS23 mutational signatures are associated with glioma recurrence and indicate worse prognosis only in low-grade type of gliomas and IDH-Mut subtype. We also identify 42 genomic features associated with distinct clinical outcome and successfully used ten of these to develop a prognostic risk model of gliomas. The high-risk glioma patients with shortened survival were characterized by high level of frequent copy number alterations including PTEN, CDKN2A/B deletion, EGFR amplification, less IDH1 or CIC gene mutations, high infiltration levels of immunosuppressive cells and activation of G2M checkpoint and Oxidative phosphorylation oncogenic pathway.
Keywords: Cancer; Genetics; Genomics
More resources
Full text:
Europe PubMed Central; PubMed Central
EndNote: Download